New cancer drug combo enters human testing
NCT ID NCT07156253
Summary
This early-stage study is testing the safety and initial effects of a new drug called SYN818 when given with an existing cancer drug, olaparib. It is for adults with advanced or metastatic solid tumors (like ovarian or breast cancer) that have specific genetic changes (BRCA mutations or HRD) and have run out of standard treatment options. The main goals are to find the safest dose and see how the body processes the drugs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
FuDan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
-
FuDan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.